In addition, in vivo experiments performed on FGF-dependent models of prostate and lung cancer confirmed the capacity of NSC12 to inhibit FGFR1 activation and to reduce tumor growth and tumor-associated angiogenesis (26, 74). Here, FGFR1 is linked to neoplasm.